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a b s t r a c t
Melioidosis, infectionwithBurkholderiapseudomallei, is being recognisedwith increasing frequencyand is
probablymore common than currently appreciated. Treatment recommendations are based on a series of
clinical trials conducted in Thailand over the past 25 years. Treatment is usually divided into two phases:
in the ﬁrst, or acute phase, parenteral drugs are given for ≥10 days with the aim of preventing death
from overwhelming sepsis; in the second, or eradication phase, oral drugs are given, usually to com-
plete a total of 20 weeks, with the aim of preventing relapse. Speciﬁc treatment for individual patients
needs to be tailored according to clinical manifestations and response, and there remain many unan-
swered questions. Some patients with very mild infections can probably be cured by oral agents alone.
Ceftazidime is the mainstay of acute-phase treatment, with carbapenems reserved for severe infections
or treatment failures and amoxicillin/clavulanic acid (co-amoxiclav) as second-line therapy. Trimetho-
prim/sulfamethoxazole (co-trimoxazole) is preferred for the eradication phase, with the alternative of
co-amoxiclav. In addition, the best available supportive care is needed, along with drainage of abscesses
whenever possible. Treatment for melioidosis is unaffordable for many in endemic areas of the develop-
ingworld, but the relative costs have reduced over the past decade. Unfortunately there is no likelihood of
any new or cheaper options becoming available in the immediate future. Recommendations for prophy-
laxis following exposure to B. pseudomallei have been made, but the evidence suggests that they would
probably only delay rather than prevent the development of infection.
© 2014 The Author. Published by Elsevier B.V. on behalf of International Society of Chemotherapy.
1. Introduction
Melioidosis is the name given to any infection caused by the
saprophytic environmental bacterium Burkholderia pseudomallei,
which is widespread in the soil and surface water in southeast
Asia and northern Australia. The disease is being recognised with
increasing frequency in known endemic areas [1,2] and new foci
are regularly being identiﬁed [3,4].
The organism is intrinsically resistant to many antimicrobial
agents, including those often used for the empirical treatment of
sepsis in the tropics [5], and may be even more resistant when
growing in bioﬁlms [6–8] and in the anaerobic acidic conditions
that might be found in vivo [9]. There is considerable evidence
supporting current treatment recommendations, mainly derived
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from a series of large randomised clinical trials conducted in north-
east Thailand since1986, although there are alsomanyunanswered
questions. This review will summarise that evidence and the cur-
rent recommendations and will consider some of the outstanding
issues.
2. Treatment
Thecurrent convention is toviewthe treatmentofmelioidosis as
comprising twophases: theﬁrst is theacutephase, theaimofwhich
is to stop patients from dying of overwhelming sepsis; the second
is the eradication phase, the aim of which is to kill any residual
bacteria and to minimise the risk of the infection relapsing.
2.1. Acute phase (Table 1)
Until 1985, the usual treatment for the acute phase was
a combination of chloramphenicol, doxycycline and trimetho-
prim/sulfamethoxazole (co-trimoxazole) (the ‘conventional’ regi-
men).However, theoverallmortalitywas37.9–61%and forpatients
with septicaemic infection and multiple foci it was as high as
87% [10]. Since there were new -lactams available that showed
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promising in vitro activity against B. pseudomallei [11], the ﬁrst
of several randomised prospective clinical trials of treatment for
melioidosis was started in Ubon Ratchathani, northeast Thailand,
in 1986 [12]. Patientswere randomised to receive the conventional
regimen or ceftazidime (120mg/kg/day) according to a paired
restricted sequential design. In total 161 patients were entered
into the study, of whom 65 had culture-proven melioidosis and
54 of these were septicaemic. The overall mortality was 37% in
those treated with ceftazidime compared with 74% in the conven-
tionally treated group, a reduction of 50% [95% conﬁdence interval
(CI) 19–81%], suggesting that ceftazidime should be adopted as the
acute-phase treatment of choice for severe melioidosis. Mortality
in patients with septicaemic melioidosis was reduced from 76% to
43%, and in patients in whom melioidosis was not conﬁrmed from
79% to 61%. Ceftazidime was given for a median of 8 days (range
7–28 days). Despite these encouraging results, it is worth noting
that 4/20 patients and 1/9 patients still had positive blood cultures
on Days 3 and 7 of treatment, respectively, and that 3 patients sub-
sequently had bacteriologically conﬁrmed relapses of melioidosis,
indications of the recalcitrant nature of the disease.
A similar study, which also took place in northeast Thailand,
was reported 3 years later [13] with broadly similar results. The
study design differed in that ceftazidime was given at a slightly
lower dose (100mg/kg/day) combined with co-trimoxazole. The
reported 7-day mortalities amongst the 61 evaluable patients with
conﬁrmed melioidosis in that study were lower than in the previ-
ous study (47% with conventional treatment compared with 18.5%
in the ceftazidime plus co-trimoxazole group overall; 57.7% com-
pared with 25% for septicaemic melioidosis; and 82.3% compared
with 30.7% for disseminated septicaemic melioidosis). No signiﬁ-
cant difference in mortality was found in patients with established
septic shock at the time of presentation. It was also reported that
no relapses were seen amongst survivors in that study.
Whether the differences between the two studies described
above reﬂected a genuinely better outcome with the combination
than with ceftazidime monotherapy, or differences in the severity
of illness between patients included in the two studies, was ini-
tiallyunclear. Twostudies comparing ceftazidimewithandwithout
co-trimoxazole undertaken in Khon Kaen and Ubon Ratchathani
were subsequently published as a single paper [14]. The overall
in-hospital mortality rates amongst all 449 patients enrolled were
not signiﬁcantly different between those treated with ceftazidime
alone (25.1%) and those treated with the combination (26.6%), nor
were there differences in death rates amongst the 241 patients
with culture-conﬁrmed melioidosis, either overall or occurring
≥48h after admission. Multiple logistic regression analysis iden-
tiﬁed that bacteraemia, respiratory failure and renal failure, but
not drug regimens, were independently associated with death and
treatment failure, even when cases with co-trimoxazole-‘resistant’
isolates were excluded. On prolonged follow-up, there was also no
difference between the two groups in terms ofmortality or culture-
conﬁrmed recurrence [15]. Thus, there is noevidence to support the
routine addition of co-trimoxazole to ceftazidime during the acute
phase of treatment formelioidosis, although somehave argued that
this is warranted in patients with undrained deep-seated infec-
tions or when monotherapy fails in places where carbapenems are
unavailable or unaffordable [16].
In an effort both to reduce the cost of treatment and to evaluate
anagentwith a spectrumof activity thatmight bemore appropriate
for monotherapy of community-acquired sepsis than ceftazidime
alone, amoxicillin/clavulanic acid (co-amoxiclav) (160mg/kg/day)
was compared with ceftazidime (120mg/kg/day) for treatment of
severe melioidosis in Ubon Ratchathani in a large, open, paired
randomised controlled trial between 1989 and 1992 [17]. In total,
379 patients were enrolled, of whom 212 proved to have culture-
positive melioidosis, with 106 patients in each treatment arm.
There were no signiﬁcant differences in mortality between the two
groups (overall 47%). The study design allowed the treating physi-
cians to switch treatment if the clinical response was considered
‘unsatisfactory’ after ≥72h, however, and this occurred more fre-
quently in the co-amoxiclav group (16/69) than in the ceftazidime
group (4/75). This is clearly a somewhat subjective endpoint, but
as a result ceftazidime was considered to remain the treatment of
choice, with co-amoxiclav as a second-line option.
The nature of the mixture of amoxicillin and clavulanic acid
means that there are complex pharmacokinetic considerations
when using it to treat melioidosis. For example, there is in vitro
evidence that relatively high concentrations of clavulanic acidmust
be achieved to potentiate amoxicillin [18], and modelling suggests
that the dosing interval for co-amoxiclav in melioidosis should
not be >6h [19]. Since different formulations and ratios of amox-
icillin to clavulanic acid are available in different countries, and
different regimens have been used by different groups to treat
melioidosis, an international consensus statementwaspublished in
2008 to reduce confusion [20]. This recommends the use of amox-
icillin/clavulanic acid at a dose of 20/5mg/kg every 4h, but only as
a second-line agent for acute-phase treatment.
Another -lactam/-lactamase inhibitor combination that
has good in vitro activity against B. pseudomallei [minimum
inhibitory concentration required to inhibit 90% of the iso-
lates (MIC90) = 4mg/L] is cefoperazone/sulbactam [21]. This was
evaluated at 25mg/kg/day in combination with co-trimoxazole
(trimethoprim 8mg/kg/day) in comparison with ceftazidime
(100mg/kg/day) plus co-trimoxazole [22]. In total, 219 patients
were enrolled, of whom 102 had culture-conﬁrmed melioidosis.
There were no signiﬁcant differences in mortality between the
two groups (18% compared with 14%, respectively) or in fever
durationor bacteriological response. This studywas, however, rela-
tively underpowered [23]. Furthermore, in a retrospective analysis
of 1353 patients with melioidosis who received cephalosporins,
the overall mortality rate for those who received cefotaxime or
ceftriaxone (71%) was signiﬁcantly higher than those receiving
ceftazidime (41.7%) or co-amoxiclav (53.9%) [24]. Ceftazidime has
thus remained the cephalosporin of choice for acute treatment of
melioidosis [25]. There is evidence that the total dose, and there-
fore costs, of ceftazidime may be reduced from 120mg/kg/day to
96mg/kg/day if it is given by continuous infusion rather than bolus
dosing [26]. To facilitate outpatient treatment with ceftazidime
and to optimise pharmacokinetics, clinicians in northern Australia
have used a simple elastomeric infusion apparatus to administer
ceftazidime [27]. This approach can save signiﬁcant expenditure
on inpatient care if the infrastructure to support outpatient par-
enteral antibiotic therapy is available, but as yet it has not been
widely adopted internationally [28]. In northern Australia there is
nowa trend towards using increasingly long courses of intravenous
(i.v.) antibiotics to treat melioidosis, especially in the presence of
deep-seated undrained foci of infection. It has been suggested that
this approach may ultimately obviate the need for an eradication
phase, although it has not been evaluated in comparative trials.
The median duration of the i.v. phase in Darwin is now 4 weeks,
and some 27% of patients have had no eradication-phase treatment
without developing relapse [29].
The carbapenems are the most active drugs against B. pseudo-
mallei in vitro [30]. There are also some theoretical reasons for
believing that they may be better therapeutic options than cef-
tazidime. For example, they exhibit longer post-antibiotic effects
[31] and are more rapidly bactericidal [30]. An open, prospective,
randomised studywas therefore conducted to compare the efﬁcacy
of ceftazidime (120mg/kg/day) with that of imipenem/cilastatin
(50mg/kg/day) for a minimum of 10 days [32]. Unfortunately, the
study had to be terminated prematurely due to the withdrawal
of pharmaceutical company support, by which time 296 patients
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had been enrolled, of whom 214 had culture-conﬁrmed melioido-
sis. There were no differences between the regimens in mortality
either overall (36.1% vs. 37.7%) or after 48h of treatment (14.8%
vs. 21.4%), but the somewhat subjective outcome of ‘treatment
failure’ was signiﬁcantly more common in patients treated with
ceftazidime (41.3% compared with 20.3%). In addition, signiﬁcantly
greater endotoxin release during treatment occurred in patients
treated with ceftazidime [33].
Latterly, meropenem has tended to be preferred over
imipenem/cilastatin as the carbapenem of choice, largely because
of lower toxicity, and in northern Australia it has been used
extensively in the treatment of severe melioidosis, albeit not in
comparative trials. In a retrospective review of 63 patients treated
with meropenem for severe melioidosis in Darwin over a 6-year
period, comparable outcomes to those with ceftazidime were
observed, with a mortality of only 19% despite a bias towards the
more severely unwell patients receiving meropenem [34]. Unfor-
tunately, a multicentre, randomised comparative study comparing
meropenem with ceftazidime in the treatment of severe melioido-
sis in northeast Thailand is currently stalled.
2.2. Eradication phase (Table 2)
The recalcitrantnatureofmelioidosiswith its tendency to recur-
rence, leading in theUSA to thenickname ‘TheVietnam timebomb’,
is well known. As improved treatment for the acute phase led to
larger numbers of survivors, it became increasingly important to
identify regimens that would reduce relapses to a minimum. Per-
haps somewhat surprisingly, it was found that ca. 25% of patients
with recurrent melioidosis actually have re-infections with a dif-
ferent strain rather than relapses of their initial infection [35].
Multivariate analysis has shown that the most important risk
factors for true relapse are the agent and duration of oral treat-
ment, followed by positive blood cultures and multifocal infection
[36].
The conventional regimen (chloramphenicol plus doxycycline
plus co-trimoxazole) was always associated with a high risk of
side effects, and furthermore there was some in vitro evidence
of the mutual antagonism of these agents [37,38] and a risk of
resistance emerging to all of them simultaneously [5]. The ﬁrst
comparative study of eradication treatment was started in Ubon
Ratchathani in 1989 and took over 3 years to complete [39]. In total,
101 patients were randomised to receive either chloramphenicol
(40mg/kg/day in fourdivideddoses)plusdoxycycline (4mg/kg/day
in two divided doses) plus co-trimoxazole (10/50mg/kg/day in
two divided doses) or co-amoxiclav with additional amoxicillin
(60mg/kg/day amoxicillin plus 15mg/kg/day clavulanic acid) for
20 weeks, with chloramphenicol being discontinued after the ﬁrst
8 weeks to reduce the risk of toxicity. Patients infected with iso-
lates exhibiting in vitro resistance to any of the study drugs or in
whom any were contraindicated were excluded. It was shown that
8 of 49 patients in the co-amoxiclav group and 2 of 52 patients
in the conventional group had culture-proven relapses, although
a number of patients were lost to follow-up. Overall compliance
was poor, with only one-half of the patients receiving the full 20
weeks of treatment, of whom two in each group relapsed, reﬂect-
ing the difﬁculties of undertaking this sort of study. Relapse rates
were higher in patients receiving co-amoxiclav (10%) as opposed
to conventional treatment (4.9%) for >12 weeks, although none of
these differences achieved statistical signiﬁcance. Poor compliance
was associated with a greater risk of relapse, as was multifocal
disease. Co-amoxiclavwas, however, better tolerated than the con-
ventional regimen, which was associated with adverse effects in
29% of cases. The conclusion of this study was that conventional
therapy was probably more effective and considerably cheaper
than co-amoxiclav,which the authors estimated to cost ca. 15 times
more than the conventional regimen at that time, and so the con-
ventional regimen would therefore usually be preferred, except in
children and pregnant or lactating women in whom the conven-
tional regimen is contraindicated.
Fluoroquinolones are only marginally active in vitro against
B. pseudomallei (MIC50 and MIC90 for ciproﬂoxacin =4mg/L) [5].
They do achieve high intracellular concentrations, however, and
since B. pseudomallei is able to survive intracellularly and is often
referred to as an intracellular pathogen (although this is a consid-
erable oversimpliﬁcation), attempts have been made to evaluate
the therapeutic efﬁcacy of this group of drugs in melioidosis. In
an open pilot study of ciproﬂoxacin (20mg/kg/day) and oﬂoxacin
(12mg/kg/day) for eradication therapy in 57 patients with melioi-
dosis, there were 13 treatment failures (5 failures to respond and 8
relapses) [40]. This disappointing failure rate of 29% suggested that
ﬂuoroquinolones should not be used for treatment of melioidosis
unless there are no alternatives. A subsequent randomised, open
study conducted at two hospitals in Thailand investigated whether
the addition of azithromycin, selected on the basis of its intracellu-
lar penetration and activity against bioﬁlms despite only moderate
in vitro activity against B. pseudomallei, might potentiate the efﬁ-
cacy of ciproﬂoxacin in the eradication phase of treatment [41]. In
total, 65 patients were randomised to receive ciproﬂoxacin plus
azithromycin for 12weeks (32 patients, of whom7 relapsed) or co-
trimoxazole plus doxycycline for 20 weeks (33 patients of whom
only 1 relapsed). This signiﬁcant difference in outcomes conﬁrms
that regimens containing ﬂuoroquinolones should not be used for
treating melioidosis.
Since the original conventional treatment was a purely empir-
ical approach comprising multiple agents, some of which are
mutually antagonistic in vitro [37] andall ofwhich can causepoten-
tially serious side effects, several studies have been conducted
to assess which components of the regimen might be omitted
without adversely affecting the outcome. The ﬁrst such study
compared the combination of chloramphenicol, doxycycline and
co-trimoxazole with doxycycline alone for a minimum of 12 weeks
in an open randomised study involving 116 patients, including 109
with culture-conﬁrmed melioidosis, of whom 87 were considered
evaluable [42]. Bacteriological relapse occurred in only one patient
treated with the four-drug combination but in 11 patients who
received doxycycline alone, and treatment failure was judged to
have occurred in 18.2% and 46.5%, respectively, suggesting that
doxycycline alone was inadequate eradication therapy for melioi-
dosis.
In a subsequent open-label randomised study, the effect of omit-
ting chloramphenicol, potentially the most toxic component of the
conventionaloral regimen,wasevaluated [43]. In total, 180patients
were randomised to receive the oral regimen with (91 patients)
or without (89 patients) chloramphenicol for the ﬁrst 4 weeks of
12–20 weeks of total treatment. The trial was terminated early due
to poor drug tolerance, particularly of the four-drug regimen (36%
requiring a switch in therapy due to side effects compared with
19%), but no signiﬁcant difference was found between the relapse
rates with the two regimens (6.6% and 5.6%, respectively), con-
ﬁrming that chloramphenicol could, or rather should, be omitted. It
was noted, however, that patients who received <12 weeks of oral
therapy had a 5.7-fold increased risk of relapse or death, emphasis-
ing the importance of compliance with prolonged oral treatment.
It is vital that this is clearly and carefully explained to patients at
every opportunity.
There remains some uncertainty regarding the optimal dos-
ing regimen for co-trimoxazole, especially given inter-regional
variations in the reported susceptibility of local strains and
the pharmacokinetics and pharmacodynamics within different
populations. A recent pharmacokinetic/pharmacodynamic mod-
elling study has suggested that previous recommendations may
D. Dance / International Journal of Antimicrobial Agents 43 (2014) 310–318 313
have resulted in underdosing of melioidosis patients in northeast
Thailand and supported the use of a weight-based regimen [44].
Co-trimoxazole alone has been used for several years for the
eradication phase of treatment in northern Australia with appar-
ently excellent results [45]. In2013, a group fromsouthernThailand
published their experienceofusingco-trimoxazolealone,with sim-
ilarly good results [46]. In a retrospective review over a 10-year
period, only 1 (3.2%) of 31 patients who received co-trimoxazole
alone relapsed compared with 5 (4.6%) of 109 treated with co-
trimoxazole plus doxycycline. Therewas a considerably higher rate
(25.7%) of gastrointestinal side effects in the latter group compared
with the group receiving co-trimoxazole alone (6.5%), and only
83.5% of the patients receiving the combination regimen were able
to complete≥20weeks of treatment as opposed to all those treated
with co-trimoxazole alone.
More recently still, the results of a large, multicentre study (the
MERTH study) conducted in north-east Thailand have been pub-
lished [47]. This study enrolled 626 patients of whom 315 were
assigned to receive co-trimoxazole plus doxycycline and 311 to
receive co-trimoxazole plus placebo for a minimum of 20 weeks
(extended beyond this on clinical grounds in 6% and 4% of cases,
respectively). Forty patients (6%) with mild and localised melioi-
dosis were treated with oral antibiotics only, whilst the others had
received prior parenteral treatment, which in 357 cases (57%) had
been given for >2 weeks. During more than 1100 person-years
of follow-up, no differences were found between the groups in
the rates of culture-conﬁrmed (7% vs. 5%) or clinically suspected
(3% in both groups) recurrences, or mortality, whether related to
melioidosis (1% vs. 3%) or overall (8% vs. 6%). On the other hand,
the risk of adverse events that required a switch of treatment (to
co-amoxiclav) was signiﬁcantly higher in the doxycycline group
(59 patients; 19%) than in the placebo group (37 patients; 12%).
Adverse drug reactions (mainly skin rashes, allergic reactions and
gastrointestinal disorders) were reported in 39% of the placebo
group and 53% of the doxycycline group overall and were clas-
siﬁed as serious adverse events (e.g. Stevens–Johnson syndrome,
severe hyponatraemia and severe hyperkalaemia) in 2% and 3%,
respectively. Recurrent melioidosis did occur in as many as 10%
of cases who were followed for 3 years after enrolment, however,
although genotyping of paired primary and recurrent isolates in
29 cases suggested that 15 (52%) were actually due to re-infection,
which tended tooccur later [median29months; interquartile range
(IQR) 13–37 months] than true relapse (median 7 months; IQR
6–13 months). The MERTH study at last conﬁrms that the treat-
ment of choice for the eradication phase of melioidosis treatment
is co-trimoxazole monotherapy [48], except in the few patients in
whom it is contraindicated or where the infecting isolate is co-
trimoxazole-resistant. The optimum duration of the eradication
phase remains to be determined, however, and further studies in
Thailand are underway to address this question.
One outstanding issue relates to the true prevalence of co-
trimoxazole resistance. Studies from Thailand have suggested that
this may be as high as 18% of isolates [49] and yet the experience
from other countries (Lao PDR, Australia, Cambodia) suggests that
it may be considerably less common than this [50]. This may partly
relate to the difﬁculty of measuring endpoints when testing co-
trimoxazole against B. pseudomallei [51,52]. It has been suggested
that disk diffusion testingmay be used as a screen to determine the
susceptibility of B. pseudomallei for this combination and that MICs
should be determined by Etest for any isolates that appear resistant
or intermediate to co-trimoxazole by disk diffusion [49]. Unfortu-
nately, no interpretive criteria for B. pseudomallei zone diameters
have been published by the Clinical and Laboratory Standards Insti-
tute (CLSI), which recommends broth microdilution testing for B.
pseudomallei against all antimicrobials [53]. Isolates with a MIC
of >2mg/L are classiﬁed as resistant, although no study has yet
demonstrated a correlation between MICs and outcome in patients
treated with co-trimoxazole alone.
2.3. Adjunctive treatment
Obviously patient management should always include the
optimal supportive treatment for sepsis available, including main-
tenance of blood pressure, adequate glycaemic control, and
management of respiratory and acute renal failure as well as
drainage of abscesses where possible.
Since the overall mortality of patients with severe melioidosis
remains high, and many of those who die do so in the ﬁrst 48h
of treatment when antibiotics are unlikely to affect the outcome,
various approaches have been tried to interrupt the inﬂammatory
cascadesandpathogenicprocesses that lead todeath, or toaugment
host defences. The ﬁrst such study involved the platelet-activating
factor receptor antagonist lexipafant [54]. The study included 131
adult Thai patients with suspected sepsis who were randomised to
receive lexipafant or placebo for up to 7 days, of whom 66 had pos-
itive blood cultures, 36 of which were B. pseudomallei. However, no
differenceswere seen between the groups in either themortality at
28 days or in any of the clinical or laboratory parametersmeasured.
Steroids and activated protein C have also been used empirically
in individual patients with sepsis caused by melioidosis but have
never been evaluated prospectively and, as with sepsis in general,
their role is unclear [55].
Neutrophils are thought to be important host effector cells in
the control of B. pseudomallei infection. Considerable interest in the
potential role of granulocyte colony-stimulating factor (G-CSF) in
melioidosis followed the publication of a retrospective review of
cases treated in northern Australia, which reported that the mor-
tality rate of melioidosis patients with septic shock was reduced
from 95% to 10% after the addition of G-CSF 300g/day for 10
days to standard treatment [56]. However, several other changes
in patient management were made concurrently and so a prospec-
tive randomised controlled study was subsequently undertaken
in Thailand [57]. In total 60 patients, 41 of whom had melioi-
dosis conﬁrmed by culture, were randomised to receive G-CSF
263g/day or placebo. Mortality rates were similar in both groups
(G-CSF group 70% vs. placebo group 87%; risk ratio 0.81, 95% CI
0.61–1.06; P=0.2), including patients with conﬁrmed melioidosis
(83% vs. 96%; P=0.3). However, patients who received G-CSF sur-
vived longer than patients who received placebo (33h vs. 18.6h;
hazard ratio =0.56, 95% CI 0.31–1.00; P=0.05). The authors con-
cluded that although G-CSF itself had not been shown to reduce
overall mortality in this relatively small study, it might ‘buy time’
for severely septic patients, allowing other measures such as cor-
rection of metabolic abnormalities and organ dysfunction that
might ultimately improve survival. It is unlikely that deﬁnitive evi-
dence to address this question will ever become available.
3. Prophylaxis (Table 3)
There are two main reasons for interest in prophylaxis against
melioidosis: the possible exposure of laboratory workers to infec-
tion and the potential use of B. pseudomallei as a weapon by
terrorists. Laboratory-acquired melioidosis has been reported,
although there are only two well-described cases, both of which
followed major lapses in laboratory technique [58,59], and there
is no evidence of infection occurring during simple manipula-
tions such as identiﬁcation and susceptibility testing. None the
less, the organism is classiﬁed as a Hazard Group 3 pathogen and
naturally anxiety occurs when laboratory staff are found to have
inadvertently handled the organism on the open bench before the
diagnosis is recognised.
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As a result, international consensus recommendations were
published in 2008 [60] and these were extended to the deliber-
ate release situation in 2012 (Table 3) [16]. It should be made
clear, however, that although there is some evidence of the par-
tial effectiveness of post-exposure prophylaxis in animal models,
particularly if given soon after exposure [61], the exposed animals
frequently go on to develop symptomatic and progressive infection
[62], and there is little reason to believe that antibiotic prophylaxis
would prevent infection in humans.
4. Unanswered questions
4.1. Do all cases need parenteral treatment?
This is unclear. It is likely that mild, localised infection can be
treated perfectly adequately with oral therapy alone, and indeed
many individual cases have been managed in this way [47]. This
speciﬁc question has, however, never been addressed in a clinical
trial and may never be. In view of the potentially severe con-
sequences of inadequate treatment, most experts recommend a
precautionary approach including an initial parenteral phase for
all except the very mildest superﬁcial localised infections.
4.2. How long should each phase of treatment last in individual
patients?
The evidence from clinical trials allows broad generalisations
to be made, but because melioidosis is so variable in its manifes-
tations, and patients with a diverse range of clinical forms of the
disease are pooled together in the analysis of clinical trials, this
does not allow speciﬁc recommendations to be made for individ-
ual patients. It is accepted that acute-phase treatment should be
given for ≥10 days, as included in the study protocols of all clin-
ical trials, but some patients who fail to defervesce or who have
undrainable deep-seated abscesses may require longer periods of
treatment. Recent analysis of data from melioidosis patients in
Ubon Ratchathani has shown that having blood cultures taken at
the end of the ﬁrst and/or second week after hospitalisation that
are positive for B. pseudomallei is strongly associated with death
(adjusted odds ratio =4.2, 95% CI 2.1–8.7, P<0.001; and adjusted
odds ratio =2.6, 95% CI 1.1–6.0, P=0.03, respectively), suggesting
that blood cultures should be repeated weekly until negative in
patients with bacteraemic melioidosis, and treatment extended if
these are positive [63]. Even in the relatively controlled circum-
stances of a clinical trial such as the MERTH study, the duration of
treatment given to individual patients varied considerably.
Similar uncertainties surround the precise duration of oral erad-
ication treatment, although it is clear that this should usually be
given for ≥12 weeks and potentially up to 20 weeks dependent on
clinical progression [36]. In this latter study, the hazard ratio for
relapse decreased by 29% for every 4-week increase in the duration
of oral treatment. A study to compare 12 weeks versus 20 weeks of
treatment with co-trimoxazole is underway in Thailand.
4.3. Are carbapenems better than ceftazidime?
There is as yet no hard evidence to support this, although sev-
eral clinicianswith experience of treating large numbers of cases of
melioidosis believe that theymaybe.Workers innorthernAustralia
have, since 1997, adopted meropenem 25mg/kg every 8h as their
preferred treatment for selected patients with melioidosis, partic-
ularly those with severe sepsis, central nervous system infection,
or relapse following ceftazidime treatment, with very favourable
results (overall mortality 19% of 63 patients) [34]. There is a trial
currently underway in Thailand comparing meropenem and cef-
tazidime, the results of which are eagerly awaited but which is
currently on hold. For the time being, at least, there is no evidence
that any agent is better than ceftazidime for reducing mortality
during the acute phase of treatment. Unfortunately, the cost of cef-
tazidime remains difﬁcult for many in endemic areas to afford: in
Laos this is currently 29000 Kip or US$3.62 per gram, so 10 days of
treatment at full doses costs nearly US$220. Although this is now
only ca. 17.5% of the 2012 Gross National Income per capita [64], as
opposed to exceeding it when melioidosis in Laos was described as
‘Pandora’s box’ a decade ago [65], this is still unaffordable for most
people. Carbapenems are not currently available in Lao PDR and are
even more expensive.
4.4. Should co-trimoxazole ever be added during the acute phase?
Despite the overall lack of clinical trial evidence of improved
outcomes when co-trimoxazole is added to ceftazidime during
acute-phase treatment, some experts still use the combination in
speciﬁc circumstances, for example in thehopeof achieving greater
penetration of active agents into sites such as prostatic or other
deep-seated abscesses or the central nervous system. It is unlikely
that clinical trials of sufﬁcient size will ever be conducted in these
speciﬁc clinical settings and so this remains a matter for individual
clinical judgement. It is certainlyworth considering inpatientswho
are deteriorating or failing to improve despite apparently adequate
treatment.
4.5. What is the clinical signiﬁcance of in vitro co-trimoxazole
resistance?
The answer to this is that we really do not know. There are
technical difﬁculties in assessing the susceptibility of B. pseudo-
mallei to co-trimoxazole and this often has to be done by Etest
or another method of measuring the MIC rather than by disk dif-
fusion testing [52]. Isolated trimethoprim resistance related to
increased expression of the BpeEF-OprC pump was found to be rel-
atively common in clinical isolates of B. pseudomallei from Thailand
and Australia, although these strains remained susceptible in vitro
to co-trimoxazole [66]. Relatively high rates of co-trimoxazole
resistance assessed by Etest (ca. 10–13%) have been reported in
isolates of B. pseudomallei from Thailand [43,49] and Malaysia [67],
although the rate amongst isolates from the LaoPDR, Cambodia and
Australia appears to be much lower than this [50]. In the compara-
tive study of conventional eradication treatment with and without
chloramphenicol [43], in vitro resistance to co-trimoxazolewas not
usedas anexclusion criterionand therewasnodifference in relapse
rate amongst those infected with co-trimoxazole-resistant strains,
although the study was underpowered to detect the signiﬁcance of
this ﬁnding. Since it is not considered ethical to give co-trimoxazole
monotherapy to patients with resistant isolates, however, alterna-
tive agents such as co-amoxiclav should be used for such patients.
4.6. Is acquired resistance a problem?
When the conventional regimen was being used extensively,
acquired resistance to chloramphenicol, which was often accom-
panied by resistance to doxycycline and co-trimoxazole, was seen
relatively frequently [5]. Resistance to the -lactams now used
for treatment has been seen to develop during treatment, usually
related tomutations in the PenA-lactamase gene that affects sub-
strate speciﬁcity, but this is relatively uncommon, especially for
carbapenems [68–72]. One unusual form of ceftazidime resistance
recently reported in six patients involved the deletion of a gene
encoding a penicillin binding protein 3 gene and was associated
with growthdefects thatmade the isolates difﬁcult to culture in the
laboratory [73]. Surprisingly high rates of resistance to ceftazidime
(10%) and co-amoxiclav (30%) have recently been reported in
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Table 1
Initial acute-phase therapy for melioidosis.a
Patient Drug Dosage/route Frequency
With no complications Ceftazidime 50mg/kg (up to 2g)
intravenous
Every 8h, or 6 g/day by
continuous infusion
after a 2g bolus
With neuromelioidosis or persistent bacteraemia or in intensive care unit Meropenem 25mg/kg (up to 1g)
intravenous
Every 8h
Adapted from [16] with permission.
a Duration of acute-phase therapy is generally 10–14 days; however, >4 weeks of parenteral therapy may be necessary in cases of more severe disease, e.g. septic shock,
deep-seated or organ abscesses, extensive lung disease, osteomyelitis, septic arthritis or neurological melioidosis. Consider adding trimethoprim/sulfamethoxazole (co-
trimoxazole) for patients with severe infection involving the brain, prostate or other privileged site (same dosing as described for eradication therapy. Can be administered
by intravenous infusion over 30–60min every 12h, or nasogastric, or oral, as appropriate). If co-trimoxazole is included, continue for the entire duration of the acute phase.
Switching to meropenem is indicated if patient condition worsens while receiving ceftazidime, e.g. organ failure, development of a new focus of infection during treatment,
or if repeat blood cultures remain positive. Depending on the severity of infection, the dose for patients >3 months can be <40mg/kg (not to exceed 2g/dose).
Table 2
Oral eradication-phase therapy for melioidosis.a
Drug Patient characteristics Recommended dosage/frequency
Trimethoprim/sulfamethoxazole (co-trimoxazole)b Adult, >60kg 160mg/800mg tablets; two tablets every 12h
Adult, 40–60kg 80mg/400mg tablets; three tablets every 12h
Adult, <40kg 160mg/800mg tablets; one tablet every 12h OR
80mg/400mg tablets; two tablets every 12h
Child 8mg/40mg per kg; maximum dose 320mg/1600mg every 12h
OR
Amoxicillin/clavulanic acid (co-amoxiclav) Adult, >60kg 500mg/125mg tablets; three tablets every 8h c
Adult, <60kg 500mg/125mg tablets; two tablets every 8h c
Child 20mg/5mg per kg every 8h; maximum dose 1000mg/250mg every 8h
Adapted from [16] with permission.
a Recommended duration of therapy is a minimum of 12 weeks.
b If the organism is susceptible and the patient does not have a documented allergy to it, oral co-trimoxazole is the agent of ﬁrst choice. If the organism is resistant to
co-trimoxazole or the patient is intolerant, the second-line choice is co-amoxiclav. Co-amoxiclav is available in different ratios and formulations depending on the source
country. Co-amoxiclav at a ratio of 4:1 is preferred to ensure there is sufﬁcient clavulanic acid [20].
c Weight-based dosage based on 20mg/5mg per kg per dose.
isolates from Brazil [74]. Co-trimoxazole resistance may also
emerge during treatment and so it is important to test isolates
obtained during treatment for susceptibility, especially when this
is associatedwith clinical deterioration. Further discussion of resis-
tance mechanisms in B. pseudomallei can be found in a recent
excellent review [75].
4.7. Are there any new treatments on the horizon?
Sadly the answer is ‘not really’. There are some drugs related to
agents that are already used to treat melioidosis that show promis-
ing in vitro activity against B. pseudomallei, such as doripenem
[76,77], biapenem [78] and tebipenem, a carbapenem marketed
in Japan of which an orally absorbed formulation is available
[79]. Tigecycline is moderately active in vitro and has given some
encouraging results in animal models but has yet to be eval-
uated in human melioidosis [77,80–82]. The monosulfactam
BAL30072 is some 2 log more active than ceftazidime and car-
bapenems against B. pseudomallei [83]. Various other classes of
compounds, such as novel quinolones like sitaﬂoxacin [84], COX-2
inhibitors [85], antimicrobial peptides [86–90], farnesol [91], CpG
oligodeoxynucleotides [92,93], glycogen synthase kinase inhibitors
[94], sulfonylureas [95], cethromycin [96], plant extracts [97–99],
snake venoms [100], methionine aminopeptidase inhibitors [101]
andmonoclonal antibody-basedapproaches [102], areunder inves-
tigation for their in vitro activity against B. pseudomallei and
therapeutic efﬁcacy in animal models, but these are a long way
from being used in human infections. These and other potential
novel therapeutic approaches for melioidosis and glanders have
recently been comprehensively reviewed [103–105].
Table 3
Post-exposure prophylaxis for melioidosis.a
Drug Patient characteristics Recommended dosage/frequency
Trimethoprim/sulfamethoxazole (co-trimoxazole) Adult, >60kg 160mg/800mg tablets; two tablets every 12h
Adult, 40–60kg 80mg/400mg tablets; three tablets every 12h
Adult, <40kg 160mg/800mg tablets; one tablet every 12h OR
80mg/400mg tablets; two tablets every 12h
Child 8mg/40mg per kg; maximum dose 320mg/1600mg every 12h
OR
Amoxicillin/clavulanic acid (co-amoxiclav) Adult, >60kg 500mg/125mg tablets; three tablets every 8h b
Adult, <60kg 500mg/125mg tablets; two tablets every 8h b
Child 20mg/5mg per kg every 8h; maximum dose 1000mg/250mg every 8h
Adapted from [16] with permission.
a Duration of post-exposure prophylaxis is 21 days. If the organism is susceptible and the patient does not have a documented allergy to it, oral co-trimoxazole is the agent
of ﬁrst choice. If the organism is resistant to co-trimoxazole or the patient is intolerant, the second-line choice is co-amoxiclav.
b Weight-based dosage based on 20mg/5mg per kg per dose.
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5. Melioidosis treatment recommendations
International consensus recommendations for the treatment
and prophylaxis of melioidosis and glanders were developed by an
expert group thatmet in Australia in 2010 and have been published
online [16]. These recommendations anticipated the results of the
MERTH study and are reproduced with permission in Tables 1–3.
There has been no subsequent evidence published that would
necessitate a change to these recommendations.
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